Karyopharm Therapeutics (KPTI) Current Assets (2012 - 2026)

Karyopharm Therapeutics (KPTI) has reported Current Assets for 15 consecutive years, with $106.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Assets rose 8.69% year-over-year to $106.4 million; the trailing twelve-month figure through Jun 2026 stood at $106.4 million (up 8.69% YoY), and the FY2025 full-year result was $103.1 million, down 34.08% from the prior year.
• Current Assets improved to $106.4 million in Q2 2026 per KPTI's latest filing, from $103.1 million in the prior quarter.
• Across five years, Current Assets topped out at $350.2 million in Q4 2022 and bottomed at $89.7 million in Q3 2025.
• Historically, Current Assets has averaged $203.8 million across 5 years, with a median of $208.5 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Current Assets increased 27.05% in 2022, then sank 53.07% in 2025.
• Over 5 years, Current Assets stood at $350.2 million in 2022, then plunged by 33.2% to $233.9 million in 2023, then slumped by 33.11% to $156.5 million in 2024, then slumped by 34.08% to $103.1 million in 2025, then gained by 3.13% to $106.4 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $106.4 million, $103.1 million, and $89.7 million for Q2 2026, Q4 2025, and Q3 2025 respectively.